Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection

Nephrology Dialysis Transplantation

Volumn 27, Issue 3, 2012, Pages 1246-1251

  Waiser, Johannes ^a   Budde, Klemens ^a   Schütz, Manuela ^a   Liefeldt, Lutz ^a   Rudolph, Birgit ^a   Schönemann, Constanze ^a   Neumayer, Hans H ^a   Lachmann, Nils ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antibody mediated rejection; Bortezomib; Kidney transplantation; Rituximab

Indexed keywords

BORTEZOMIB; CREATININE; CYCLOSPORIN A; IMMUNOGLOBULIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RITUXIMAB; TACROLIMUS;

ADULT; ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; SINGLE DRUG DOSE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BORONIC ACIDS; CHILD; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMAPHERESIS; PROGNOSIS; PYRAZINES; SURVIVAL RATE; YOUNG ADULT;

EID: 84861112343     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr465     Document Type: Article

References (28)

1. Lefaucheur C, Superbielle-Boissel C, Hill GS et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324-331
2. Einecke G, Sis B, Reeve J et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531
3. Pei R, Lee JH, Shih NJ, ChenMet al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43-49
4. Lachmann N, Terasaki PI, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513
5. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408-415
6. Zou Y, Stastny P, Susal C et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293-1300
7. Dragun D, Müller DN, Bräsen JH et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-569
8. Pascual M, Saidman S, Tolkoff-Rubin N et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 35: 158-162
9. Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033-1041
10. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895
11. Jordan SC, Quartel AW, Czer LS et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800-805
12. Rocha PN, Butterfly DW, Greenberg A et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75: 1490-1495
13. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840
14. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251
15. Tydén G, Kumlien G, Genberg H et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145-148
16. Kaposztas Z, Podder H, Mauiyyedi S et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23: 63-73
17. Lefaucheur C, Nochy D, Andrade J et al. Comparison of combination plasmapheresis / IVIg / anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099-1107
18. Mulley WR, Hudson FJ, Tait BD et al. A single low-fixed dose of rituximab to salvage renal transplants fromrefractory antibody-mediated rejection. Transplantation 2009; 87: 286-289
19. Faguer S, Kamar N, Guilbeaud-Frugier C et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277-1280
20. Rostaing L, Guilbeau-Frugier C, Kamar N. Rituximab for humoral rejection after kidney transplantation: an update. Transplantation 2009; 87: 1261
21. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761
22. Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201-209
23. Trivedi HL, Terasaki PI, Feroz A et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555-1561
24. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681-686
25. Flechner SM, Fatica R, Askar M et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90: 1486-1492
26. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760
27. Sis B, Mengel M, Haas M et al. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471
28. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612